Skip to main content

Perceptive Advisors — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$24.4B
Total invested
$125.0M
Avg. check
25
Industries
Biotechnology 20Health Care 19Medical 10Therapeutics 10Pharmaceutical 8Medical Device 5+19 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 224
Rapport Therapeutics
September 2025

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Biotechnology · Boston$250.0M Post-IPO Equity
Synlogic
September 2023

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.

Biotechnology · Cambridge$21.0M Post-IPO Equity
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post-IPO Equity
Satellos Bioscience
September 2025

Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration.

Health Care · Toronto$754K Post-IPO Equity
Willow
September 2022

Willow is a women's healthcare company that develops pumping bras and breast pumps for women.

Baby · Mountain ViewSeries D
HilleVax
September 2023

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.

Biopharma · Boston$100.0M Post-IPO Equity
Point Biopharma
September 2022

Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.

Biopharma · Indianapolis$125.0M Post-IPO Equity
Forge Biologics
September 2022

Forge Biologics is a gene therapy development engine, enabling access to life changing gene therapy programs.

Biotechnology · Grove City$90.0M Series C
Amylyx Pharmaceuticals
September 2025

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.

Biotechnology · Cambridge$175.0M Post-IPO Equity
Poseida Therapeutics
August 2023

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Biopharma · San Diego$25.0M Post-IPO Equity
Frequency Therapeutics
August 2022

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.

Biotechnology · LexingtonPost-IPO Equity
scPharmaceuticals
August 2024

ScPharmaceuticals is a biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.

Biotechnology · Lexington$125.0M Post-IPO Debt
CinCor Pharma
August 2022

CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.

Biotechnology · Cincinnati$225.0M Post-IPO Equity
MeiraGTx
July 2026

MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.

Biotechnology · New York$125.0M Post-IPO Debt
DarioHealth
July 2026

DarioHealth is a digital therapeutics company engaged in the development and commercialization of patented and proprietary technology.

Health Care · New York$23.5M Post-IPO Equity
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
Clearside Biomedical
July 2026

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Biotechnology · Alpharetta$3.0M Post-IPO Debt
BridgeBio
July 2026

BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Biotechnology · Palo Alto$1.0B Post-IPO Equity
IDEAYA Biosciences
June 2026

IDEAYA Biosciences is an oncology-focused biotechnology company that develops therapeutics for patients with genetically-defined cancers.

Biotechnology · South San Francisco$345.0M Post-IPO Equity
CereVasc
June 2026

CereVasc is a medical device company that develops a minimally invasive treatment option for communicating hydrocephalus.

Biotechnology · Charlestown$85.0M Series C
Pyxis Oncology
June 2026

Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.

Biotechnology · Boston$50.0M Post-IPO Equity
Blueprint Medicines
June 2022

Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.

Bioinformatics · Cambridge$1.3B Post-IPO Equity
4D Molecular Therapeutics
June 2026

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$200.0M Post-IPO Debt
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note

Where Perceptive Advisors invests

Biotechnology20
Health Care19
Medical10
Therapeutics10
Pharmaceutical8
Medical Device5

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 25 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post-IPO Equity round. Perceptive Advisors's total known invested capital is $24.4B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $125.0M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include Rapport Therapeutics, Synlogic, Pepgen, Satellos Bioscience, Willow. These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →